Bisoprolol
| Clinical data | |
|---|---|
| Trade names | Zebeta, Monocor, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693024 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | >90% |
| Protein binding | 30% |
| Metabolism | 50% liver, CYP2D6, CYP3A4 |
| Elimination half-life | 10–12 hours |
| Excretion | Kidney, fecal (<2%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.108.941 |
| Chemical and physical data | |
| Formula | C18H31NO4 |
| Molar mass | 325.449 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Bisoprolol, sold under the brand names Bisotab, Concor, Corbis and Zebeta among others, is a beta blocker which is selective for the beta-1 receptor and used for cardiovascular diseases, including tachyarrhythmias, high blood pressure, angina, and heart failure. It is taken by mouth.
Common side effects include headache, feeling tired, diarrhea, and swelling in the legs. More severe side effects include worsening asthma, blocking the ability to recognize low blood sugar, and worsening heart failure. There are concerns that use during pregnancy may be harmful to the baby.
Bisoprolol was patented in 1976 and approved for medical use in 1986. It was approved for medical use in the United States in 1992.
Bisoprolol is on the World Health Organization's List of Essential Medicines and is available as a generic medication. In 2022, it was the 249th most commonly prescribed medication in the United States, with more than 1 million prescriptions.